Big Pharma's Internationalization of R&amp;D to China

Grimes, Seamus; Miozzo, Marcela

doi:10.1080/09654313.2015.1029442

Cited by 22 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GSK conforms to the industry-wide focus on China as a key growth market. GSK had invested USD 6.09 billion by 2012 whilst generating only 1.6 per cent of global sales in the country according to figures from 2013 (Grimes and Miozzo, 2015). Head of GSK Consumer Healthcare Business for Asia Pacific, Middle East, and Africa, Zubair Ahmed, declared in 2016 that "the sheer importance of China to our business is humongous," going on to explain that "China is the single biggest market in the Asia, Middle East & Africa (AMA) region in terms of size, and is certainly the one with the biggest growth potential" (Ding, 2016).…”

Section: The Allure Of Mainland China As An Emerging Marketmentioning

confidence: 99%

The Importance of Leverage in GlaxoSmithKline’s China Engagement: A Revelatory Case Study

Thorley

Fulda

2020

Journal of Current Chinese Affairs

View full text Add to dashboard Cite

This article critically examines multinational corporation (MNC)–host government relations in the People’s Republic of China (PRC) through the prism of the GlaxoSmithKline (GSK) corruption scandal. The article takes the episode as a revelatory case study and analyses it with a view to uncovering further data on the imperatives that govern interactions between the PRC and MNCs. Drawing upon the theoretical framework provided by David M. Anderson’s conception of leverage, the authors attempt to unite the two themes of cultural analysis and commercial analysis. By highlighting both the rising commercial risks for MNCs and considerable legal risks for Chinese and non-Chinese intermediaries working on their behalf, the case itself underlines a gulf between theoretical understanding and practical experience of engagement with China in this sphere. The authors argue that the GSK corruption case demonstrates both that MNC normative bargaining leverage (the use of standards and norms, considered legitimate by both sides, to gain advantage or protect one’s position) in the PRC is illusory and that the Chinese party-state possesses far greater negative bargaining leverage (leverage based upon the capacity to make the other side worse off) than typically assumed.

show abstract

Section: The Allure Of Mainland China As An Emerging Marketmentioning

confidence: 99%

The Importance of Leverage in GlaxoSmithKline’s China Engagement: A Revelatory Case Study

Thorley

Fulda

2020

Journal of Current Chinese Affairs

View full text Add to dashboard Cite

show abstract

“…The leading position of China as a country in which to search for IP can be compared with the increasing trend for western firms to establish pharmaceutical facilities in China (after China's WTO entry in 2001, most of the big pharma companies entered the Chinese market, manufactured drugs and carried out less expensive medical and clinical trials and R&D), despite a rather fragmented but promising market for drugs (Grimes, and Miozzo, 2015). As a smaller but also promising and growing market Korea receives approximately one third of the applications of transnational drug patents, while Japan lagged behind, receiving only 17% of transnational pharmaceutical patent applications.…”

Section: Sample Analysismentioning

confidence: 99%

Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter

Laurens¹,

Bas²,

Schoen

2019

IJTM

View full text Add to dashboard Cite

The paper deals with the determinants of worldwide IP coverage of patented inventions in large pharmaceutical firms. We support the core idea that the internationalisation of firm R&D and an economic presence in a foreign country are positive key factors which explains global IP coverage. For the global pharmaceutical industry, we estimate probit models on the probability that a patent will be expanded worldwide. We retain two categories of worldwide patent: the well-known triadic patent and the new triadic one (triadic + China + Korea). The data set encompasses the 17,633 priority patents applied for by 76 enterprises from several countries over the period 2003-2005. One important finding is that patenting in Japan sets up an important barrier, giving Japanese firms an advantage when triadic patenting is considered. For European and US firms, our estimation results confirm the idea that the level of firm R&D internationalisation is a significant explanatory factor in international IP coverage, together with control variables. We highlight an inverted U-shaped relationship between these two variables. The hypothesis related to a firm economic presence is also verified.

show abstract

“…Chia-Wen et al (2015) found that a firm’s experience in foreign expansion may have a positive impact on the relationship between R&D internationalization and innovation performance. Grimes and Miozzo (2015) analyzed the challenges and opportunities in the early stages of establishing R&D centers in emerging markets, providing a more subtle perspective on R&D internationalization in emerging regions.…”

Section: Literature Reviewmentioning

confidence: 99%

Exploring the Asian innovation networks (AINs) characteristics

Liu

2017

Information Development

View full text Add to dashboard Cite

In this study, we attempted to fill an important gap that literature has yet to investigate: the characteristics of the Asian Innovation Networks. This paper depicts the characteristics of the Asian Innovation Networks for four main emerging technologies: 3D printing technology, big data technology, integrated circuit technology and carbon nanotubes and graphene technology. The networks’ characteristics are presented by calculating the different network centrality indicators. In order to show these characteristics intuitively, the visualization method was also used. Both methods are based on an analysis of patents and patent data are collected from the European Patent Office (EPO) database. The results indicate that Japan ranks first in betweenness centrality, while China has the highest degree centrality among nearly all the emerging technologies. In the carbon nanotubes and graphene technology innovation network, India has tight interactions with South Korea, and Iran is closely related to Malaysia. Thailand plays an important role in the big data technology innovation network. The centrality trend for Asian countries in innovation networks has gradually decreased. This could be useful for developing Asian countries to make international scientific and technological collaboration strategies and policies in the future.

show abstract

Big Pharma's Internationalization of R&D to China

Cited by 22 publications

References 49 publications

The Importance of Leverage in GlaxoSmithKline’s China Engagement: A Revelatory Case Study

The Importance of Leverage in GlaxoSmithKline’s China Engagement: A Revelatory Case Study

Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter

Exploring the Asian innovation networks (AINs) characteristics

Contact Info

Product

Resources

About